Dept. of the Army -- USAMRAA Grants

Dept. of the Army -- USAMRAA

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception<strong><em>.</em></strong></p><p><strong>Distinctive Features:</strong></p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The research team must include two or more breast cancer consumer advocates.</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. </strong>For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and &nbsp;Partnering PI) applications by the deadline may result in administrative withdrawal.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Era of Hope Scholar Award supports individuals who are early in their careers with significant potential to effect meaningful change in breast cancer. As the Intent of the FY26 BCRP Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the award’s central features include the Principal Investigator’s (PI’s) demonstrated ability to go beyond conventional thinking in their field and the innovative and meaningful contributions that they can make toward ending breast cancer. The Era of Hope Scholar Award requires exceptionally talented scientists that are among “the best and the brightest” in their field(s), with demonstrated experience forming effective partnerships and collaborations and strong potential for future leadership in breast cancer research. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.</p><p><strong>Distinctive Features:</strong></p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award.</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The research team must include two or more breast cancer consumer advocates.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Concept Award supports highly innovative, untested, potentially groundbreaking concepts, theories, paradigms and/or basic kidney cancer research. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation in kidney cancer. Applications must describe how the new concept will be innovative and present a novel course of investigation in the field of kidney cancer. </p><p><strong>Distinctive Features: </strong></p><p>•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Preliminary data are not allowed. </strong></p><p>•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>This is a blinded funding mechanism. </strong>Applications to this funding opportunity will undergo a double-blinded peer review. Applications must not include any materials that may identify the Principal Investigator (PI), a collaborator, or the organization of the PI or collaborator. </p><p>•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong><em>Due to the blinded nature of the review process, identifying or making references to the PI, collaborator(s), or their organization(s) in the proposal (Project Narrative, List of Abbreviations, Acronyms, Symbols, Statement of Work, Impact Statement and Innovation Statement) is prohibited and will result in administrative rejection of the application.&nbsp;</em></strong></p>

Dept. of the Army -- USAMRAA

<p>Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Research Advancement Award supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP portfolio-specific strategic goals.</p><p><br></p><p>Distinctive Features: Applications must include preliminary data. The Research Advancement Award supports use-inspired basic research to further or validate preliminary findings for short- and long-term impact. Proposed research projects may range from hypothesis testing to expansion of mature data.</p><p><br></p><p>Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $19.6M to fund approximately 14 Research Advancement Award applications with total cost caps of $1.4M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.</p>

Dept. of the Army -- USAMRAA

DoW Peer Reviewed Medical, Technology/Therapeutic Development Award

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Idea Development Award (IDA) supports conceptually innovative and high-impact research that could ultimately lead to critical discoveries in tuberous sclerosis complex (TSC) research and/or improvements in patient care.</p><p><br></p><p><strong>Distinctive Features:<em> This funding mechanism allows for established and new-to-the-field investigators. </em></strong>New-to-the-field investigators are independent investigators that are early in their faculty appointments and/or established investigators transitioned from other research fields into TSC research. Applications to the New-to-the-Field option will compete separately from the Established Investigators submitting to the regular Idea Development Award (IDA).</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).</p><p><br></p><p><strong>Distinctive Features:</strong> <strong><em>This funding mechanism allows for multiple Principal Investigators (PIs).</em></strong> Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field.</p><p><br></p><p><strong>Distinctive Features: </strong>Preliminary Data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.</p>

Dept. of the Army -- USAMRAA

DoW Tuberous Sclerosis Complex, Idea Development Award

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Early Investigator Research Award (EIRA) supports Multiple Sclerosis-focused research opportunities for individuals in the early stages of their careers, under the guidance of one or more designated Mentors. All applications must address at least one of the FY26 MSRP EIRA focus areas.</p><p><br></p><p><strong>Distinctive Features: </strong>This opportunity allows for early-stage investigators to develop a research project, investigate a problem or question in MS research, and further their intellectual development as an MS researcher of the future. <strong><em>All application components for the EIRA are expected to be written by the Principal Investigator (PI), with appropriate direction from the Mentor(s).</em></strong></p>

Dept. of the Army -- USAMRAA

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Exploration – Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the Multiple Sclerosis (MS) research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. All applications must address at least one of the FY26 MSRP EHDA focus areas. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.<strong><em> The presentation of preliminary and/or published data is not required.</em></strong></p><p><br></p><p><strong>Distinctive Features:</strong> This funding mechanism includes two options: <strong>Established Investigator </strong>and <strong>New Investigator.</strong> The New Investigator option supports applicants early in their faculty appointments.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Epilepsy Research Program (ERP) seeks to advance post-traumatic epilepsy (PTE) research through development of investigators new to the PTE field. To accomplish this, the ERP is soliciting Faculty members to join the Virtual Post-Traumatic Epilepsy Research Center (ViP-TERC). The ERP ViP-TERC is a unique, interactive virtual research center providing intensive mentoring, national networking, collaborations, and a peer group for new PTE investigators. The overarching goal of the ViP-TERC is to develop successful, highly productive PTE researchers in a collaborative research and career development environment to enhance quality and expand quantity of the PTE research field.</p><p><br></p><p><strong>Distinctive Features: </strong>This award mechanism focuses on both the Faculty member’s research and career potential. The mechanism requires the Faculty member to designate a Career Guide. The Career Guide must have a track record of successful mentorship coupled with a strong record of funding and publications.</p><p><br></p><p>**NEW for FY26** An investigator may be named on only one FY26 ERP Virtual Post-Traumatic Epilepsy Research Center – Faculty Award application as a Principal Investigator.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary: </strong>The intent of the Epilepsy Research Program (ERP) Research Partnership Award is to support new or existing research partnerships focused on collaboratively addressing critical questions relevant to post-traumatic epilepsy (PTE) in a manner that would be unachievable through separate efforts. It is expected that investigators will utilize their distinct but complementary perspectives to synergistically address a central problem or question critical to PTE research and those living with PTE, their families and/or their care partners.</p><p><br></p><p><strong>Distinctive Features:</strong> This funding mechanism requires that a minimum of two investigators partner in one overarching study. Only the Initiating Principal Investigator (PI) will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. </p><p><br></p><p>**NEW for FY26** An investigator may be named on only one FY26 ERP Research Partnership Award application as a PI.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Epilepsy Research Program (ERP) Idea Development Award (IDA) solicits novel research that has the potential to increase understanding of post-traumatic epilepsy (PTE) and associated comorbidities to improve quality of life, especially in Service Members, Veterans and/or their care partners. The work should innovatively challenge existing research paradigms, exhibit high levels of creativity and be a new research direction for the investigator. The IDA is NOT intended to expand or extend previously published findings or continue a line of research already well-established in the Principal Investigator’s (PI’s) laboratory.</p><p><br></p><p><strong>Distinctive Features:</strong></p><p>•The IDA offers funding for investigators at all career levels.</p><p>•**NEW for FY26** An investigator may be named on only one FY26 ERP IDA application as a PI.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The intent of the fiscal year 2026 (FY26) Epilepsy Research Program (ERP) Leveraging Research Award is to support basic, translational and/or clinical research that repurposes or expands existing research resources to accelerate the understanding of post-traumatic epilepsy (PTE) and associated comorbidities.</p><p><br></p><p><strong>Distinctive Features: </strong></p><ul><li>The study must adapt an existing cohort, resource, research tool, or intervention for which PTE was not a prior focus or application.</li><li>**NEW for FY26** An investigator may be named on only one FY26 ERP Leveraging Research Award application as a Principal Investigator.</li></ul>

Dept. of the Army -- USAMRAA

DoW Epilepsy Virtual Post-Traumatic Epilepsy Research Center &ndash; Faculty Award

Dept. of the Army -- USAMRAA

<p>Summary: This funding mechanism supports high-risk/high-reward research that has the potential to make a major impact in lupus research and/or lupus disease. The emphasis is on impact. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Impact Award (IPA) focus areas. This funding mechanism does not allow clinical trials.</p><p><br></p><p>Distinctive Features: The FY26 LRP IPA encourages, but does not require, preliminary data.</p><p>An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, IPA, Transformative Vision Development Award, Transformative Vision Award), for a maximum of four applications to the FY26 LRP.</p>

Dept. of the Army -- USAMRAA

<p>Summary: This funding mechanism supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. The emphasis is on innovation. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Idea Award (IA) focus areas. This funding mechanism does not allow clinical trials.</p><p><br></p><p>Distinctive Features:</p><p>• Early-career investigators are eligible to serve as Principal Investigators (PIs) on applications to the FY26 LRP Idea Award (see Section 2. Eligibility Information).</p><p>• Preliminary data are permitted but not required.</p><p>• Applications should describe future directions of the work.</p><p>• An individual may be named as PI on only one application per LRP award mechanism (IA, Impact Award, Transformative Vision Development Award, Transformative Vision Award), for a maximum of four applications to the FY26 LRP</p>

Dept. of the Army -- USAMRAA

<p>Summary: This funding mechanism supports interventional research at the individual and/or health care system level which will result in near-term impact on the health-related quality of life of individuals living with lupus. The emphasis is on near-term impact on quality of life. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Transformative Vision Award (TVA) focus areas. This mechanism allows for clinical trials but does not allow animal studies.</p><p><br></p><p>Distinctive Features:</p><p>• Applications must include preliminary data.</p><p>• Applications must include at least one lupus consumer advocate as a member of the research team.</p><p>• This funding mechanism allows for up to three Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application(s) is rejected or administratively withdrawn.</p><p>• An individual may be named as PI on only one application per LRP award mechanism (Idea Award, Impact Award, Transformative Vision Development Award, TVA), for a maximum of four applications to the FY26 LRP.</p>

Dept. of the Army -- USAMRAA

DoW Lung Cancer Idea Development Award

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. All applications must address one of the <a href="https://militaryhealth-my.sharepoint-mil.us/personal/teresa_m_parkerreeser_civ_health_mil/Documents/Documents/FY%202026/PCRP/HT942526PCRPIDA_for%20GO%20review.docx#Overarching_Challenges" target="_blank">FY26 PCRP Overarching Challenges</a>.</p> <p><strong>Distinctive Features:</strong><strong style="color: red;"> </strong></p> <p><span style="color: black;">·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><strong>New Investigator Category:</strong> In addition to established investigators, the FY26 PCRP Idea Development Award encourages research ideas from investigators in the early stages of their careers (i.e., within 10 years after completion of their terminal degree). Qualified new investigators must identify a collaborator(s) experienced in prostate cancer research. <span style="color: rgb(0, 176, 80);">&nbsp;</span></p> <p><br></p> <p><a href="https://cdmrp.health.mil/pubs/press/2026/pcrppreann" target="_blank">https://cdmrp.health.mil/pubs/press/2026/pcrppreann</a></p>

Dept. of the Army -- USAMRAA

DoW Prostate Cancer, Physician Research Award

Dept. of the Army -- USAMRAA

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Patient-Centered Outcomes and Survivorship Award (PCOSA) promotes evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research must address at least one of the FY26 LCRP areas of emphasis in the Health Outcomes and Survivorship category.</p><p><br></p><p><strong>Distinctive Features:</strong></p><p>• This funding mechanism requires the research team to include an advocate who is a lung cancer patient/survivor or caregiver.</p><p>• This funding mechanism allows proposed projects to include translational or clinical research, including pilot clinical trials.</p>

Dept. of the Army -- USAMRAA

<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.</p><p><br></p><p><strong>Distinctive Features:</strong> This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 – Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 – Pilot clinical trials of novel interventions.</p>